Muhammad Shipa

Muhammad Shipa

Auto-generated profile, based on publicly available information

Muhammad Shipa

Centre for Rheumatology, Division of Medicine, University College London, London, UK. Rayne Institute, 5 University St, Bloomsbury, London WC1E 6JF UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Annals of Internal Medicine
Verified
Journal Article
Closed access
MSMuhammad Shipa
Muhammad Shipa
AEAndrew Embleton-Thirsk
Andrew Embleton-Thirsk
MPMariea Parvaz
Mariea Parvaz
LSLiliana Ribeiro Santos
Liliana Ribeiro Santos
PMPatrick Muller
Patrick Muller
SHSally Hamour
Sally Hamour
Rituximab is commonly used for patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable responses. This phase 2 clinical trial sought to o... Visual Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus. Rituximab is commonly used for patients with systemic lupus erythematosus (SLE) that is refractory to con... Background: B-cell depletion with rituximab is commonly used for patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable responses. We hy...

4 May 2021 in Rheumatology
Verified
Journal Article
Open access
PDF file
MSMuhammad Ruhul Amin Shipa
Muhammad Ruhul Amin Shipa
SYSu-Ann Yeoh
Su-Ann Yeoh
AEAndrew Embleton-Thirsk
Andrew Embleton-Thirsk
DMDev Mukerjee
Dev Mukerjee
MEMichael R Ehrenstein
Michael R Ehrenstein
To determine whether concomitant HCQ modulates the increase in erythrocyte mean corpuscular volume (MCV) caused by MTX therapy, and whether this is associated with improved clinical response in RA. A retrospective observational analysis was conducted on two independent hospital datasets of biologic-naïve, early-RA patients who started oral MTX. Baseline characteristics, DAS28-ESR and monthly MCV after starting MTX were obtained. Conventional and machine-learning statistical approaches were applied to the discovery cohort (Cohort 1, 655 patients) and results validated using Cohort 2 (225 patients). HCQ therapy with MTX was associated with a 2-fold increase in the likelihood of response defined in this study as clinical remission or low disease activity at 6 months (P <0.001). The improved clinical outcome of combination HCQ and MTX therapy was associated with an accelerated rise in MCV from 2 months after commencing therapy. The increase in MCV at 3 months was equivalent to the contemporaneous reduction in the DAS (DAS28-ESR) in predicting clinical response at 6 months. Using latent class mixed modelling, five trajectories of MCV change over 6 months from baseline were identified. The odds ratio of response to treatment was 16.2 (95% CI 5.7, 46.4, P 5 fl class, which contained the most patients, compared with MTX alone. Our data provide mechanistic insight into the synergistic clinical benefit of concomitant HCQ with MTX, boosting the rise in MCV, which could serve as a companion biomarker of treatment response.

28 May 2022 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
MSMuhammad Ra Shipa
Muhammad Ra Shipa
NHNicola Heyer
Nicola Heyer
RMRashid Mansoor
Rashid Mansoor
CDClaire T. Deakin
Claire T. Deakin
AMAnastasia-Vasiliki Madenidou
Anastasia-Vasiliki Madenidou
DSDebajit Sen
Debajit Sen
To analyse and compare drug-survival of adalimumab and etanercept (and their biosimilars) in biologic-naïve patients with ERA (Enthesitis-Related Arthritis). In this retrospective observational study, conventional statistics and machine-learning were applied to compare drug-survival (adalimumab, etanercept and their biosimilars initiated: 2009-2019) in ERA and identify determinants. The primary outcome was discontinuation of treatment due to primary- or secondary-failure and adverse drug-reactions. During the observation period, 99 of 188 patients with ERA on first-line TNF inhibitors (etanercept-n=108, adalimumab-n=80) discontinued their treatment (median survival-time 3.9years, 95%CI 2.6-4.9years). Adalimumab was associated with longer drug-survival compared to etanercept especially after an initial positive response, with the median time to treatment discontinuation 4.9years (95% CI 3.9-5.7) for adalimumab, compared to 2years (95%CI 1.4-4.0) for etanercept (HR of treatment-discontinuation-0.49, 95%CI 0.32--0.75, p=0.001). Adjusted by propensity-score, adalimumab-methotrexate combination was associated with longer drug survival, compared to adalimumab-monotherapy (HR-0.41, 95%CI 0.20-0.85), etanercept-monotherapy (HR-0.28, 95%CI 0.15-0.53), and etanercept-methotrexate combination (HR-0.39, 95%CI 0.21-0.73). The presence of HLA-B27 was associated with longer drug-survival (HR-0.50, 95%CI 0.29-0.87) following an initial positive response. Higher-CRP at baseline was associated with higher rate of primary-failure (HR-1.68, 95%CI 1.08-2.62). Axial-ERA (sacroiliitis±spinal-involvement) was associated with poorer drug-survival for both primary- and secondary-failure (overall HR-2.03, 95%CI 1.22-3.40). Adjusted by propensity-score, shorter drug-survival was observed in patients with baseline-CRP≥12.15 mg/L, but only in the context of axial-ERA, not in peripheral-ERA (no sacroiliitis/spinal-involvement) (HR-2.28, 95%CI 1.13--3.64). Following an initial positive primary response, continuing methotrexate with adalimumab was associated with the longest drug-survival compared to adalimumab-monotherapy or etanercept-based regimens. Axial-ERA was associated with a poorer drug-survival. A CRP >12.15 in patients with axial-ERA was associated with a higher rate of primary-failure. Further prospective studies are required to confirm these findings.

1 December 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
MSMuhammad Ruhul Amin Shipa
Muhammad Ruhul Amin Shipa
RARaj Amarnani
Raj Amarnani
SYSu-Ann Yeoh
Su-Ann Yeoh
MMM D Mainuddin
M D Mainuddin
MEMichael R Ehrenstein
Michael R Ehrenstein

1 June 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
MGM. Greenwood
M. Greenwood
MSM. Shipa
M. Shipa
MEM. Ehrenstein
M. Ehrenstein
Background: Considerable evidence suggesting enhanced efficacy of anti-TNF therapy for rheumatoid arthritis (RA) when co-administered with methotrexate (MTX) led us to explore the applicability of the published data to our patient cohort. Objectives: This retrospective study aimed to investigate the efficacy of MTX in combination with adalimumab (ADA) and etanercept (ETN) for RA, examining changes in disease activity score (DAS28-CRP) on first starting treatment, and rates of withdrawal due to inefficacy over up to 10 years of treatment in routine clinical practice. Methods: 309 patients with RA who had started ADA or ETN as a first-line biologic at UCLH from 2003 onwards were identified. Demographic and treatment details, DAS28-CRP (DAS) at the biologic-naïve baseline and at a first appointment for review on anti-TNF were extracted from clinical records. ANOVA was used to investigate the level of association between change in DAS and anti-TNF type, concomitant therapy, anti-CCP (CCP), rheumatoid factor (RF), age, disease duration and number of DMARD trials by anti-TNF initiation, year of initiation and gender. Kaplan-Meier with log rank tests were used to explore associations between anti-TNF type, MTX, CCP and RF and rates of withdrawal due to inefficacy, and Cox Proportional Hazards to check whether these remained significant after controlling for any other significant factors. Results: 179 patients were on ADA and 130 ETN; 44% were on concomitant MTX (Table 1). Numbers of patients co-prescribed MTX with ADA or ETN according to CCP status Variables in the Cox Model Conclusion: There was no apparent benefit of MTX with anti-TNF with respect to initial DAS response, but MTX was associated with a reduction in withdrawals for inefficacy though only in CCP positive patients treated with ETN. Disclosure of Interests: None declared

30 August 2022 in Portuguese Journal of Nephrology & Hypertension
Verified
Journal Article
Closed access
LSLiliana Santos
Liliana Santos
MSMuhammad Shipa
Muhammad Shipa
JLJosé António Lopes
José António Lopes
MEMichael Ehrenstein
Michael Ehrenstein